Shanghai Pharmaceuticals: Approval for Production of Diprophylline Injection

Shanghai Pharmaceuticals announced that its subsidiary Shanghai Hefeng Pharmaceutical Co., Ltd. has received the "Drug Registration Certificate" issued by the National Medical Products Administration for its dipropylline injection, and production has been approved. This drug is classified as a chemical drug class 3, and is suitable for relieving symptoms of bronchial asthma, asthma-related bronchitis, and other respiratory conditions. As of the date of the announcement, the company has invested approximately 3.14 million yuan in research and development expenses. According to IQVIA data, the amount of hospital procurement for this dosage form in mainland China is estimated to reach 325 million yuan by 2025. The company stated that the approval of this product will help enhance market competitiveness and accumulate experience for future applications for generic drugs. However, due to factors such as policies and market conditions, there is a risk of sales not meeting expectations.